Medicinal Cannabis: Limited Evidence for Most Indications with Notable Safety Concerns
Based on the most recent 2024 ASCO guidelines and 2026 systematic reviews, medicinal cannabis shows only modest benefits for chemotherapy-induced nausea/vomiting and cancer pain when standard treatments fail, but lacks robust evidence for chronic pain, sleep disorders, anxiety, and depression—with significant safety concerns including psychiatric risks, drug interactions, and cannabis use disorder development. 1
Evidence Quality and Certainty
The 2024 ASCO guideline systematically evaluated cannabis evidence across multiple outcomes, revealing predominantly low to very low certainty evidence for most indications 1:
- Moderate certainty: Dronabinol and nabilone for chemotherapy-induced nausea/vomiting; nabiximols for cancer pain; oral cannabinoids for sleep in chronic cancer pain patients
- Low certainty: High-dose oral CBD for total symptom burden; various cannabinoids for appetite/weight, quality of life
- Very low certainty: All cannabinoids for anxiety and depression
A critical limitation across all evidence is that studies used varying interventions, small sample sizes, short follow-up periods, and lack standardized manufacturing practices 1.
Efficacy by Indication
Cancer-Related Symptoms
Chemotherapy-induced nausea/vomiting: Cannabis may provide benefit when standard antiemetics fail, but this represents a second-line or rescue therapy only, not first-line treatment 1. The evidence base predates modern antiemetic regimens, limiting applicability.
Cancer pain: Nabiximols shows moderate certainty evidence for benefit, though the effect size is modest 1. Importantly, there is no evidence supporting cannabis for treating cancer itself 1.
Chronic Non-Cancer Pain
The 2021 BMJ meta-analysis (32 trials, 5,174 patients) found that non-inhaled medical cannabis produces only a small improvement in pain relief (0.5 cm reduction on 10 cm VAS scale—barely reaching the minimal important difference) with moderate certainty evidence 2. A 2026 overview of systematic reviews confirmed low to moderate certainty of benefits for chronic non-cancer pain 3.
The 2026 Canadian real-world study showed improvements in pain scores at 24 weeks, but none met minimal clinically significant thresholds 4. This disconnect between statistical significance and clinical meaningfulness is critical.
Sleep Disturbances
Evidence is mixed and indirect. The ASCO guideline found moderate certainty that oral cannabinoids improve sleep specifically in patients with chronic cancer pain 1. The 2021 BMJ meta-analysis showed a very small improvement in sleep quality (0.35 cm on 10 cm VAS, high certainty) 2. However, the 2026 overview found results pointing to lack of benefits for sleep disorders when assessed as a primary outcome 3.
The 2023 MASCC guideline specifically concluded: "There is no high-quality evidence to recommend the use of cannabis as an intervention for psychological symptoms [including insomnia] in patients with cancer" 5.
Anxiety and Depression
The evidence here is particularly weak. The ASCO guideline rated evidence as very low certainty for anxiety and depression across all cannabinoid types 1. The 2023 MASCC guideline found no studies specifically assessing efficacy on psychological symptoms as primary outcomes in cancer patients 5.
The 2026 Lancet Psychiatry meta-analysis (54 trials, 2,477 participants) found no significant effects on anxiety disorders when assessed as primary outcomes, though some reduction in anxiety symptoms when measured secondarily 6. For depression, there was an absence of RCT evidence 6.
A second 2026 systematic review found cannabinoids reduced anxiety symptoms (SMD=-0.40) but noted this evidence came predominantly from symptoms measured as secondary outcomes in other primary conditions, with very low certainty and high heterogeneity 7.
Other Indications
The 2026 Lancet Psychiatry review found some evidence for:
- Cannabis use disorder: THC/CBD combination reduced withdrawal symptoms and weekly cannabis use 6
- Tic/Tourette's syndrome: Reduction in tic severity 6
- Autism spectrum disorder: Reduction in autistic traits 6
However, cannabinoids worsened cocaine craving in cocaine use disorder 6.
Critical Safety Concerns
Common Adverse Effects
The ASCO guideline identifies frequent side effects 1:
- Drowsiness, dizziness, confusion, dry mouth
- Dizziness risk increases substantially with longer use: 9% at <3 months vs. 28% at ≥3 months (high certainty) 2
The 2021 BMJ meta-analysis confirmed increased risk of:
- Cognitive impairment (2% absolute risk increase)
- Vomiting (3%), drowsiness (5%), nausea (5%)
- Impaired attention (3%)
- Dizziness (9-28% depending on duration) 2
Serious Safety Issues
Psychiatric risks are substantial and often underappreciated 1:
- Racing heartbeat, extreme dizziness/confusion
- Paranoia and psychosis (breaks with reality)
- 10% of chronic users develop cannabis use disorder with clinically significant impairment
- Medical cannabis card holders have nearly 2x higher incidence of cannabis use disorder (17% vs 9% within 12 weeks)
- May exacerbate psychiatric disorders in vulnerable individuals
- Associated with increased risk of depressive disorders
- Early onset use (especially weekly/daily) strongly predicts future dependence
Drug interactions 1:
- Immunotherapy: Cannabis may reduce efficacy—patients on immunotherapy should avoid cannabis
- Pain and anxiety medications: Cannabis potentiates side effects
- Timing separation from other medications may be necessary
Cardiovascular effects: Arrhythmias and orthostatic hypotension possible, though no evidence of increased long-term cardiovascular mortality 1
Cannabis hyperemesis syndrome: Paradoxical severe nausea/vomiting with high-dose chronic use, relieved only by hot showers and cannabis cessation 1
Driving safety: Cannabis users are more than twice as likely to be involved in motor vehicle crashes 1. Patients must avoid driving for 5-8 hours minimum after use, potentially longer for some individuals.
Vulnerable Populations
Older adults face higher risk of confusion and falls 1. This is particularly concerning given that many patients seeking cannabis for chronic pain are elderly.
Awareness Gap
A 2025 survey of cancer survivors found alarmingly low awareness of health risks 8:
- Only 5% aware of suicidal thought risk
- Only 6% aware of intense nausea/vomiting risk
- Only 11% aware of depression risk
- Only 14% aware of anxiety risk
- Only 35% aware of drug interaction risks
This knowledge gap is dangerous given that 17.4% of cancer survivors are current cannabis users 8.
Clinical Algorithm for Decision-Making
Step 1: Assess Indication Appropriateness
Consider cannabis ONLY if:
- Chemotherapy-induced nausea/vomiting refractory to standard antiemetics, OR
- Cancer pain inadequately controlled with standard analgesics, OR
- Chronic non-cancer pain with failed conventional therapies (recognizing minimal benefit)
Do NOT use for:
- First-line treatment of any condition
- Primary treatment of anxiety or depression
- Sleep disorders as primary indication
- Cancer treatment itself
Step 2: Screen for Contraindications
Absolute contraindications:
- Current immunotherapy treatment
- History of psychosis or severe psychiatric disorders
- Active cannabis use disorder
Relative contraindications requiring careful consideration:
- Age >65 years (fall risk)
- Concurrent CNS depressants
- Cardiovascular disease
- Occupations requiring driving
- History of substance use disorders
Step 3: Route Selection
Prefer oral administration (edibles) over inhalation 1:
- Onset: 2 hours to full effect
- Warn patients about delayed onset to prevent overdosing
- Avoid smoked or vaped forms due to respiratory concerns
Step 4: Monitoring Protocol
Mandatory discussions 1:
- THC and CBD content of products
- Frequency and timing of use
- Subjective effects
- Source and cost
- Concurrent medications
- Driving plans (enforce 5-8 hour minimum wait time)
Regular assessment for:
- Cannabis use disorder development (10% baseline risk)
- Psychiatric symptoms (depression, anxiety, psychosis)
- Cognitive impairment
- Falls (especially elderly)
- Treatment efficacy vs. side effect burden
Step 5: Set Realistic Expectations
Inform patients that:
- Benefits are small to very small for most conditions
- Evidence quality is predominantly low to very low
- No condition shows large, clinically transformative effects
- Adverse events are common (NNTH=7 for any adverse event) 2
- Risk of developing cannabis use disorder is substantial
Common Pitfalls to Avoid
Assuming cannabis is "natural" and therefore safe: The psychiatric risks, drug interactions, and potential for use disorder are real and significant.
Using cannabis as first-line therapy: Evidence supports only second-line or rescue use after conventional treatments fail.
Ignoring the immunotherapy interaction: This is a critical safety issue that could compromise cancer treatment outcomes 1.
Failing to counsel about driving: The 2x crash risk is substantial and medicolegally important 1.
Not screening for psychiatric vulnerability: History of psychosis is a strong contraindication 1.
Overlooking the evidence quality: Most recommendations rest on low or very low certainty evidence with high heterogeneity 1, 5, 3, 6, 7.
Assuming patient-reported benefits equal clinical efficacy: The 2026 Canadian study showed that despite patient-reported improvements, outcomes failed to meet minimal clinically significant thresholds 4.
Bottom Line for Clinical Practice
The 2024-2026 evidence base reveals that medicinal cannabis has a very limited role in clinical practice, restricted primarily to refractory chemotherapy-induced nausea/vomiting and inadequately controlled cancer pain. For chronic non-cancer pain, sleep, anxiety, and depression—the most common reasons patients seek cannabis—the evidence shows at best small benefits that may not reach clinical significance, coupled with notable safety concerns including psychiatric risks, drug interactions, and substantial potential for cannabis use disorder development.
The routine use of cannabinoids for mental disorders, substance use disorders, and most pain conditions is currently rarely justified given the scarcity of high-quality evidence 6. When cannabis is considered after conventional therapies fail, clinicians must engage in detailed informed consent discussions covering the modest expected benefits, significant safety risks, and the low certainty of the supporting evidence.